Berkeley Capital Partners LLC Sells 467 Shares of bluebird bio, Inc. (NASDAQ:BLUE)
Berkeley Capital Partners LLC lowered its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 15.1% during the second quarter, Holdings Channel reports. The firm owned 2,630 shares of the biotechnology company’s stock after selling 467 shares during the period. Berkeley Capital Partners LLC’s holdings in bluebird bio were worth $276,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in bluebird bio by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,220 shares of the biotechnology company’s stock valued at $4,210,000 after buying an additional 540 shares during the period. Macquarie Group Ltd. acquired a new position in bluebird bio during the fourth quarter valued at $703,000. Candriam Luxembourg S.C.A. increased its position in bluebird bio by 17.5% in the first quarter. Candriam Luxembourg S.C.A. now owns 161,000 shares of the biotechnology company’s stock valued at $14,636,000 after buying an additional 24,000 shares during the period. First Mercantile Trust Co. increased its position in bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 365 shares during the period. Finally, Strs Ohio increased its position in bluebird bio by 40.5% in the first quarter. Strs Ohio now owns 5,900 shares of the biotechnology company’s stock valued at $536,000 after buying an additional 1,700 shares during the period.
Shares of bluebird bio, Inc. (NASDAQ BLUE) opened at 93.95 on Friday. The company has a 50 day moving average of $98.52 and a 200 day moving average of $90.12. The firm’s market capitalization is $4.28 billion. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by $0.07. The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. bluebird bio’s quarterly revenue was up 977.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.59) EPS. On average, analysts anticipate that bluebird bio, Inc. will post ($6.78) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Berkeley Capital Partners LLC Sells 467 Shares of bluebird bio, Inc. (NASDAQ:BLUE)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/12/berkeley-capital-partners-llc-sells-467-shares-of-bluebird-bio-inc-nasdaqblue.html.
Several equities analysts have weighed in on BLUE shares. Zacks Investment Research downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. BTIG Research restated a “buy” rating on shares of bluebird bio in a report on Monday, May 1st. Maxim Group restated a “hold” rating on shares of bluebird bio in a report on Friday, May 5th. Morgan Stanley raised their target price on shares of bluebird bio from $87.00 to $91.00 and gave the company an “equal weight” rating in a report on Monday, May 8th. Finally, Standpoint Research started coverage on shares of bluebird bio in a report on Tuesday, May 30th. They set a “buy” rating and a $110.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $100.66.
In other news, insider Nick Leschly sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $108.05, for a total value of $2,701,250.00. Following the transaction, the insider now owns 360,656 shares in the company, valued at approximately $38,968,880.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Lynch sold 2,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $80.00, for a total value of $160,000.00. Following the completion of the transaction, the director now owns 3,400 shares in the company, valued at approximately $272,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 77,856 shares of company stock worth $8,093,145. Corporate insiders own 3.90% of the company’s stock.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.